Trials / Terminated
TerminatedNCT04655599
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Arena Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
Detailed description
This is a single-center, randomized, crossover, double-blind, placebo-controlled study designed to evaluate the effects of olorinab on gastric, small-bowel, and colonic transit in IBS participants with predominant constipation (IBS-C) or with predominant diarrhea (IBS-D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olorinab | Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5. |
| DRUG | Placebo | Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5. |
Timeline
- Start date
- 2021-01-29
- Primary completion
- 2021-04-13
- Completion
- 2021-04-13
- First posted
- 2020-12-07
- Last updated
- 2021-05-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04655599. Inclusion in this directory is not an endorsement.